Kaya Holdings (KAYS) Income from Continuing Operations (2011 - 2025)
Kaya Holdings (KAYS) recorded quarterly Income from Continuing Operations of 8591465.0 in Q3 2025, down 229.26% quarter-over-quarter from 2609336.0 in Q2 2025, and down 258.32% on a YoY basis from 5426571.86 in Q3 2024.
Kaya Holdings (KAYS) Income from Continuing Operations (2011 - 2025) Analysis & Trends
Kaya Holdings' Income from Continuing Operations history runs 15 years deep, the most recent figure standing at 8591465.0 for Q3 2025.
- In Q3 2025, Income from Continuing Operations fell 258.32% year-over-year to 8591465.0; the TTM figure through Sep 2025 stood at 11912295.0 (down 301.4% YoY), while the FY2024 annual figure was 2060111.0, down 239.52% from the prior year.
- Income from Continuing Operations was 8591465.0 for Q3 2025 at Kaya Holdings, down from 2609336.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 9096960.0 in Q2 2021 to a low of 8591465.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 365746.89 across 5 years, with a median of 34933.0 in 2023.
- Biggest YoY gain for Income from Continuing Operations was 1505.88% in 2024; the steepest drop was 3094.09% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 2650418.0 in 2021, then plunged by 32.0% to 1802212.0 in 2022, then sank by 96.67% to 60080.0 in 2023, then surged by 1505.88% to 964814.0 in 2024, then slumped by 990.48% to 8591465.0 in 2025.
- The last three Income from Continuing Operations figures came in at 8591465.0 (Q3 2025), 2609336.0 (Q2 2025), and 1676308.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Kaya Holdings | - | - | 5,370.00 | -8.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -8.59 Mn |
| Jun 30, 2025 | -2.61 Mn |
| Mar 31, 2025 | -1.68 Mn |
| Dec 31, 2024 | 964,814.00 |
| Sep 30, 2024 | -2.40 Mn |
| Jun 30, 2024 | 415,873.00 |
| Mar 31, 2024 | -1.05 Mn |
| Dec 31, 2023 | 60,080.00 |
| Sep 30, 2023 | 2.10 Mn |
| Jun 30, 2023 | -714,156.00 |
| Mar 31, 2023 | 34,933.00 |
| Dec 31, 2022 | 1.80 Mn |
| Sep 30, 2022 | -7.44 Mn |
| Jun 30, 2022 | 3.07 Mn |
| Mar 31, 2022 | -1.10 Mn |
| Dec 31, 2021 | 2.65 Mn |
| Sep 30, 2021 | 3.93 Mn |
| Jun 30, 2021 | 9.10 Mn |
| Mar 31, 2021 | -5.51 Mn |
| Dec 31, 2020 | 3.26 Mn |